Skip to content
The Kids Research Institute Australia logo
Donate

Search

Primary Nasal Epithelial Cells as a Surrogate Cell Culture Model for Type-II Alveolar Cells to Study ABCA-3 Deficiency

ATP Binding Cassette Subfamily A Member 3 (ABCA-3) is a lipid transporter protein highly expressed in type-II alveolar (AT-II) cells. Mutations in ABCA3 can result in severe respiratory disease in infants and children. To study ABCA-3 deficiency in vitro, primary AT-II cells would be the cell culture of choice although sample accessibility is limited. Our aim was to investigate the suitability of primary nasal epithelial cells, as a surrogate culture model for AT-II cells, to study ABCA-3 deficiency.

Comparison of home ambulatory type 2 polysomnography with a portable monitoring device and in-laboratory type 1 polysomnography for the diagnosis of obstructive sleep apnea in children

To compare type 2 polysomnography (T2PSG) to the gold standard type 1 in-laboratory polysomnography (T1PSG) for diagnosing obstructive sleep apnea (OSA) in children; validate home T2PSG in children with suspected OSA.

A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosis

The marked heterogeneity in cystic fibrosis (CF) disease complicates the selection of those most likely to benefit from existing or emergent treatments. We aimed to predict the progression of bronchiectasis in preschool children with CF.

Dysregulated Notch Signaling in the Airway Epithelium of Children with Wheeze

The airway epithelium of children with wheeze is characterized by defective repair that contributes to disease pathobiology. Dysregulation of developmental processes controlled by Notch has been identified in chronic asthma. However, its role in airway epithelial cells of young children with wheeze, particularly during repair, is yet to be determined.

Phage therapy for multi-drug resistant respiratory tract infections

The emergence of multi-drug resistant (MDR) bacteria is recognised today as one of the greatest challenges to public health. As traditional antimicrobials are becoming ineffective and research into new antibiotics is diminishing, a number of alternative treatments for MDR bacteria have been receiving greater attention. Bacteriophage therapies are being revisited and present a promising opportunity to reduce the burden of bacterial infection in this post-antibiotic era.

Respiratory researcher named joint winner of prestigious Premier’s Science Award

Congratulations to respiratory health researcher and clinician Dr Pam Laird, who was last night named joint winner of Early Career Scientist of the Year at the 2024 Premier’s Science Awards.

New drug offers hope for people living with cystic fibrosis

A promising new treatment pioneered in Western Australia for people with cystic fibrosis has commenced testing in a clinical trial in the United States and Australia.

The Kids Research Institute Australia researchers take out prestigious Premier’s Science Awards

Three outstanding researchers have won 2023 Premier’s Science Awards, with another inducted into the prestigious WA Science Hall of Fame.

The Kids researchers named as finalists in 2023 Premier’s Science Awards

Five The Kids Research Institute Australia researchers working across diverse and highly impactful areas of child health research have been named as finalists for the 2023 Premier’s Science Awards.

The Kids Research Institute Australia researchers awarded $11 million to support vital child health research

Researchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.